Introduction
============

Glioblastoma (GBM) is the most common primary adult brain tumor, and it continues to have a dismal median survival of 15 months despite maximal safe surgical resection with radiotherapy and chemotherapy ([@b1-ijo-54-06-2039]-[@b3-ijo-54-06-2039]). A deeper understanding of the mechanisms driving the aggressiveness of and high levels of therapeutic resistance in GBM is needed in order to develop novel effective therapies. GBM is well characterized as a pathway-driven disease ([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039]) with alterations in receptor tyrosine kinases (RTKs), activating mutations in PI3CA (p110) and PIK3R1 (p85) or the loss of phosphatase and tensin homolog (PTEN) occurring in up to 88% of GBM cases ([@b6-ijo-54-06-2039]), which promotes the conversion of phosphatidylinositol ([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])-bisphosphate \[Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~\] into phosphatidylinositol ([@b3-ijo-54-06-2039],[@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])-trisphosphate \[Ptdlns([@b3-ijo-54-06-2039],[@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~3~\]. The accumulation of Ptdlns([@b3-ijo-54-06-2039],[@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~3~ promotes the localization of proteins containing pleckstrin homology (PH) domains to the plasma membrane, enhancing downstream signaling, such as the activation of AKT and mammalian target of rapamycin complex (mTORC), promoting cancer growth and therapeutic resistance ([@b7-ijo-54-06-2039]), as well as oncogenic transformation ([@b8-ijo-54-06-2039]). Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~ has important functions in cell migration ([@b9-ijo-54-06-2039]) and calcium regulation ([@b10-ijo-54-06-2039]).

Myristoylated alanine-rich C-kinase substrate (MARCKS) is an intrinsically unstructured protein highly expressed in the brain that was originally thought to be an 80 kDa protein by SDS gel electrophoresis due to its unique amino acid composition ([@b11-ijo-54-06-2039]), but later shown to be 31.75 kDa by cDNA sequencing and mass spectrometry ([@b10-ijo-54-06-2039]-[@b15-ijo-54-06-2039]). The MARCKS effector domain (ED) is known to electrostatically sequester Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~ at the plasma membrane, blocking its cleavage by phospholipase C (PLC) or phosphorylation by phosphatidylinositide 3-kinase (PI3K) ([@b13-ijo-54-06-2039],[@b16-ijo-54-06-2039]) and crosslink filamentous actin (F-actin) ([@b10-ijo-54-06-2039],[@b14-ijo-54-06-2039],[@b17-ijo-54-06-2039],[@b18-ijo-54-06-2039]). The ability of MARCKS to sequester Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~, renders it potentially as a potent tumor suppressor when membrane-bound due to the frequency of PI3K hyperactivation and the loss of PTEN in GBM. MARCKS has two domains that promote plasma membrane binding, an N-terminal myristoylation moiety and an electrostatically charged ED. Myristoylation alone has been shown to be insufficient for membrane binding, instead, requiring contributions from its cationic ED ([@b13-ijo-54-06-2039]). MARCKS membrane binding is electrostatically maintained through the attraction of the positively charged lysine residues of the ED (+13) to negatively charged phospholipid head groups, such as Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~ ([@b19-ijo-54-06-2039]), and by the embedding of phenylalanine residues of the ED into the acyl chain regions of the phospholipids in the membrane ([@b20-ijo-54-06-2039]). MARCKS plasma membrane and actin binding are regulated through two major mechanisms: i) The phosphorylation of up to four serine residues in the ED by PKC ([@b21-ijo-54-06-2039]) or ROCK kinases ([@b22-ijo-54-06-2039]); and ii) the binding of the ED by calcium (Ca^2+^)/calmodulin(CaM) ([@b16-ijo-54-06-2039],[@b17-ijo-54-06-2039]). These events, however, are mutually exclusive, allowing competitive interactions to occur at MARCKS ED, enabling 'crosstalk' across distinct signaling pathways ([@b13-ijo-54-06-2039]). MARCKS crosslinking of F-actin at the plasma membrane is lost either with ED phosphorylation or Ca^2+^/CaM binding ([@b14-ijo-54-06-2039],[@b17-ijo-54-06-2039],[@b18-ijo-54-06-2039]). In addition to Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~ sequestration and F-actin crosslinking, MARCKS ED binds phosphatidylserine (PS) ([@b23-ijo-54-06-2039],[@b24-ijo-54-06-2039]), and functions as a nuclear localization sequence (NLS) ([@b25-ijo-54-06-2039]). In cancer, MARCKS expression has been associated with both tumor-suppressing and tumor-promoting phenotypes ([@b26-ijo-54-06-2039]-[@b29-ijo-54-06-2039]); however, its inconsistent role in cancer progression has been attributed to a lack of information on ED phosphorylation status until more recent studies ([@b10-ijo-54-06-2039],[@b14-ijo-54-06-2039],[@b30-ijo-54-06-2039]-[@b32-ijo-54-06-2039]). In GBM, Micallef *et al* previously demonstrated that the epidermal growth factor receptor variant III (EGFR-VIII) invasive phenotype was driven in part by the phosphorylation of MARCKS ED ([@b32-ijo-54-06-2039]). Additionally, Jarboe *et al* demonstrated that the knockdown of MARCKS in GBM promoted cell proliferation and radiation resistance through upregulations in non-homologous end joining (NHEJ) DNA repair mechanisms, and that patients with a high MARCKS expression, particularly in MGMT unmethylated GBM tumors, had substantial survival benefits ([@b33-ijo-54-06-2039]). Since MARCKS itself is not mutated in GBM ([@b34-ijo-54-06-2039]), it is suggested that primarily epigenetic, post-transcriptional or post-translational modifications will overcome the MARCKS tumor-suppressing effects.

In this study, we further examine the hypothesis that MARCKS functions as a tumor suppressor in GBM, by overexpressing MARCKS and investigating its effects on growth suppression and radiation sensitivity. We hypothesized that the unphosphorylated ED would have growth-suppressing and radiation-sensitizing effects, while ED phosphorylation would block these tumor-suppressing effects.

Materials and methods
=====================

Cells and cell culture
----------------------

U87 and U373 glioblastoma lines were originally acquired from the University of Uppsala (Uppsala, Sweden), and 293FT cells were acquired from ATCC (Manassas, VA, USA). All cell lines were cultured as previously described in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C and 5% CO~2~ ([@b33-ijo-54-06-2039]). All tetracycline inductions were accomplished at 2 *µ*g/ml doxycycline in complete DMEM.

MARCKS plasmid production
-------------------------

U87 cells were engineered to overexpress MARCKS or the MARCKS ED mutants in a tetracycline-dependent manner as previously described ([@b25-ijo-54-06-2039]). Other ED mutants were similarly constructed. Concisely, the ViraPower HiPerform T-REx Gateway Expression System (cat. no. A11141) and the pENTR221 entry vector containing the wild-type (WT) sequence was purchased from Thermo Fisher Scientific (Waltham, MA, USA). The pENTR221-MARCKS vector was cloned into the pLenti6.3/TO/V5-DEST destination vector. Mutant MARCKS ED constructs were synthesized by and cloned into the pUC57 vector by GenScript (Piscataway, NJ, USA). Fragments from these plasmids with the mutations were cloned into the pLenti6.3/TO/V5-MARCKS-WT using restriction sites and standard protocols to generate MARCKS mutant lentiviral plasmids containing blasticidin resistance and a V-5 epitope tag. An empty vector control plasmid (CTL) was also generated.

Lentiviral particle production
------------------------------

Lentiviral particles were produced as previously described ([@b33-ijo-54-06-2039]). Concisely, lentivirus was generated by co-transfection of 293FT cells with an appropriate amount of MARCKS pLenti6.3/TO/V5 plasmid, pCMV-VSV-G envelope plasmid (Addgene plasmid 8454) and psPAX2 packaging plasmid (Addgene plasmid 12260) (both from Addgene, Watertown, MA, USA) with Lipofectamine 2000 (cat. no. 11668) in Opti-MEM (cat. no. 11058) (both from Thermo Fisher Scientific). The medium was changed the following morning, and enriched viral medium was collected 24 h later, filtered through a 0.45-*µ*m filter, aliquoted and stored at -80°C. Lentivirus was quantified using QuickTiter p24 ELISA (Cell Biolabs, Inc., San Diego, CA, USA).

Stable cell line selection and validation
-----------------------------------------

U87 cells were first transduced with p24 quantified tetracycline-repressor (Tet-R) packaged lentiviral particles along with 8 *µ*g/ml polybrene as previously described ([@b25-ijo-54-06-2039]). A total of 500 *µ*g/ml Geneticin (G418; Life Technologies/Thermo Fisher Scientific) was used to select for Tet-R-positive cells. Tet-R-positive cells were subsequently transduced with similar amounts of p24 quantified CTL, WT+, NP, PP or ΔED lentiviral particles. Subsequently, 1 *µ*g/ml blasticidin was used to select successfully transduced cells. Robust tetracycline-dependent MARCKS expression was validated by western blot analysis following a 72-h induction with 2 *µ*g/ml of doxycycline (Life Technologies/Thermo Fisher Scientific) or the phosphate-buffered saline vehicle control. MARCKS mutations were additionally validated by PCR amplification using CMV forward primer (5′-CGCAAATGGGCGGTAGGCGTG-3′) and V5 reverse primer (5′-ACCGAGGAGAGGGTTAGGGAT-3′) coupled and sequenced using Sanger sequencing of an internal MARCKS forward primer (5′-GAACGGACAGGAGGATGG-3′) and V5 reverse primer (5′-ACCGAGGAGAGGGTTAGGGAT-3′).

Western blot analysis and antibodies
------------------------------------

Western blot analysis was performed as previously described ([@b35-ijo-54-06-2039]). Briefly, chilled mammalian protein extraction reagent (MPER) lysis buffer (cat. no. 78501; Pierce/Thermo Fisher Scientific, Rockford, IL, USA) was supplemented with protease (\#P8340) and phosphatase inhibitors (P0044 and P5726) (both from Sigma-Aldrich, St. Louis, MO, USA) before lysing the cells for 30 min on ice. The samples were subsequently centrifuged at 12,000 × g for 10 min at 4°C, and the supernatant was collected and quantified using the Pierce BCA protein assay kit. Samples were separated by electrophoresis through a 10% SDS-polyacrylamide gel (SDS-PAGE) and transferred onto a PVDF membrane (Immobilon, Emdmilipore, Burlington, MA, USA). The blots were blocked in 5% BSA for 1 h and probed with the following antibodies at 4°C overnight with gentle rocking using manufacturer recommended dilutions: V5-HRP (P/N 46-0708; Invitrogen/Thermo Fisher Scientific), MARCKS anti-rabbit (ab52616), MARCKS anti-mouse (ab55451) (both from Abcam, Cambridge, MA, USA), phosphorylated (p-)histone H2AX S139 (9718S), p-Akt (Ser473; D9E; \#4060), p-Akt (Thr308; C31E5E; \#2965), Akt (C67E7; \#4691), PKCα (\#2056) (all from Cell Signaling Technology, Danvers, MA, USA), rabbit IgG control (20304E; Imgenex/Novus Biologicals, Centennial, CO, USA) and Actin (sc-1616-R), lamin A/C (sc-7292), α-tubulin (sc-53646) (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA). The blots were treated with secondary HRP antibody at 1:5,000 for 1 h at room temperature with gentle rocking, and detected with enhanced chemiluminescence (ECL) using Western Lighting-Plus ECL substrate (PerkinElmer, Inc., Waltham, MA, USA) and blue X-ray film. Densitometry was performed using ImageJ software with 8-bit images and normalized to the loading control.

Isolation of nuclear and cytoplasmic fractionations
---------------------------------------------------

Plate and doxycycline induce for 72 h a sufficient number of cells to have approximately 10 million cells in a pellet following collection. The modified nuclear extraction protocol (\#40410; Active Motif, Carlsbad, CA, USA) was as follows: The cells were collected by removing the media and washing with 1X ice-cold PBS. This was followed by the addition of 1.5 ml cold PBS and 1 ml trypsin per plate until the cells lifted. The cells were then transferred to a 15 ml centrifuge tube and spun for 5 min at 400 × g at 4°C. The supernatant discarded, and the cells were then rinsed once more with 2 ml ice-cold PBS and spun for 5 min at 400 × g at 4°C and the supernatant was removed. The pellet was resuspended in 1 ml of ice-cold 1X hypotonic buffer, with gentle pipetting up and down and transferring to a chilled 1.5 ml micro-centrifuge tube and incubation on ice for 30 min. Subsequently, 50 *µ*l detergent was added and the mixture was vortexed for 10 sec at the highest setting, and then spun for 2 min at 14,000 × g at 4°C. The supernatant was then transferred (cytoplasmic fraction) into a new chilled micro-centrifuge tube and frozen at -20°C for western blot analysis. The remaining fluid was aspirated until only the pellet remained. The pellet was then rinsed with 1 ml 1X PBS and spun down for 2 min at 14,000 × g at 4°C to aspirate off the supernatant. Nuclear extraction was continued using 50 *µ*l of complete MPER lysis buffer supplemented with protease (\#P8340) and phosphatase inhibitors (P0044 and P5726) (both from Sigma-Aldrich) for 30 min on ice. The mixture was then spun for 2 min at 14,000 × g at 4°C, and the supernatant was collected and frozen at -20°C for western blot analysis (nuclear fraction). Protein determination and probing was performed for western blot analysis using the above-mentioned protocol.

Cell proliferation assay
------------------------

A total of 5,000 cells per well (n=12) were counted using a hemocytometer and plated for each of the validated MARCKS mutant lines into black 96-well plates containing 100 *µ*l of DMEM with 10% FBS and 2 *µ*g/ml of the doxycycline (doxycycline medium). The U87 ATP levels were measured using a PerkinElmer ATPlite Luminescence Assay System (PerkinElmer, Waltham, MA, USA) as per the manufacturer's instructions at 5-7 days after plating. U373 cell viability was determined using same plating conditions (5,000 cells/well 100 *µ*l), however, using a CellTiter Glo (Promega, Madison, WI, USA) kit as per the manufacturer's protocol (n=4). Luminescence was determined on a BioTek H1 Hybrid Synergy (BioTek, Winooski, VT, USA).

Colony formation and clonogenic survival assay
----------------------------------------------

The clonogenic assay was performed as previously described ([@b33-ijo-54-06-2039]). In brief, one-step clonogenic fixation and staining solution were made by combining 750 ml of deionized water with 250 ml of 25% glutaraldehyde (G6257-1L; Sigma-Aldrich) and 5 g of crystal violet (C581-100; Thermo Fisher Scientific) in a 1 liter bottle and mixing at room temperature until the mixture was dissolved. Cells were then doxycycline-induced for 72 h before counting using a hemocytometer and diluting to a defined concentration. Pre-determined cell numbers were plated in 60-mm dishes with a 4 ml total volume and allowed to attach overnight before irradiating in a single fraction at indicated doses for clonogenic assay (colony formation assay does not receive irradiation). Fourteen days after plating, cells were fixed and stained with the clonogenic staining solution for 30 min at room temperature, before gently rinsing plates with cold tap water and drying upside-down overnight. Colonies were counted at ×45 magnification using a dissecting microscope (Stereomaster/Thermo Fisher Scientific, Pittsburgh, PA, USA) and were determined in the presence of \>50 cells. The surviving fraction (SF) was calculated by using the following equation: (number of colonies formed/number of cells plated)/(number of colonies from the sham-irradiated group/number of cells plated). Results are plotted in a semi-logarithmic format using GraphPad Prism 7.04 and standard error of the mean (SEM) error bars. Dose enhancement ratio=(dose (Gy) for control (CTL)/dose for ED mutant) at SF=0.2.

Immunofluorescence staining, and quantification of fluorescence intensity and localization on the image cytometer Xcyto10
-------------------------------------------------------------------------------------------------------------------------

In total, 50,000 cells were plated in a 24-well plate containing 12 mm poly-D-Lysine coated round coverslips and 500 *µ*l doxycycline-containing medium. Cells were induced for 72 h before the medium was removed. The cells were then rinsed with 1 ml room temperature PBS and fixed with 500 *µ*l of 4% paraformaldehyde for 12 min at room temperature. The cells were then permeabilized with 0.1% Triton X-100 PBS for 20 min and blocked in 5% BSA, 1% goat serum PBS for 40 min at room temperature. Subsequently, 250 *µ*l of 1:250 primary antibody in 0.5% BSA was added per coverslip and incubated overnight at 4°C. Coverslips were rinsed 3 times for 5 min with 500 *µ*l PBS before a 2-h room temperature incubation in the dark with 1:1,000 AlexaFluor 546 anti-rabbit IgG secondary antibody (A11010) and 1X phalloidin-FITC (F432) (both from Invitrogen/Thermo Fisher Scientific) dye in 0.5% BSA PBS. The cells were then rinsed with 500 *µ*l PBS 3 times for 5 min before co-staining with 1:1,000 BlueMask-1 (ChemoMetec, Allerod, Denmark) and 1:250 DAPI (2 *µ*g/ml) at for 30 min at room temperature. Coverslips were rinsed in 500 *µ*l 1X PBS for 5 min before mounting on Xcyto 2-Sample slides (ChemoMetec) with ProLong Glass Antifade mountant with DAPI (Thermo Fisher Scientific) overnight in the dark. Slides were analyzed on the image cytometer Xcyto10 (ChemoMetec) at ×20 magnification with excitation/filter sets AF546 (LED535; 582-636), AF488 (LED488; 513-555), MASK (LED405; 430-475) DAPI (LED405; 573-613) for high-resolution images and the quantification of fluorescent intensities and localization. Similarity scores were calculated using XcytoView (ChemoMetec) and represent the log-transformed Pearson's correlation coefficients between two channels. Similarity scores between MARCKS and DNA were used to determine MARCKS relative nuclear localization, and similarity scores between MARCKS and phalloidin were used to compare MARCKS and F-actin association.

Quantification of γH2AX foci formation
--------------------------------------

Cells were adhered to 12 mm poly-D-Lysine-coated round coverslips (REF354086; Corning, Inc., Corning, NY, USA) in 500 *µ*l medium containing doxycycline for 72 h prior to 8 Gy irradiation or 0 Gy (Sham). Cells were fixed at indicated time-points with ice-cold methanol for 12 min at -20°C and blocking with 5% BSA 1% goat serum for 40 min. 1:400 Histone H2AX S139 (9718S; Cell Signaling Technology) primary and 1:1,000 AlexaFluor 488 (ab150077; Abcam) secondary antibodies were used to stain for γH2AX and coverslips were subsequently stained with DAPI and BlueMask-1. Coverslips were mounted slides using with ProLong diamond anti-fade mountant. Cells were imaged on EVOS FL (Thermo Fisher Scientific) microscope at ×20 magnification, with 4 images per time-point collected and were scored by blinded observers. Positive events were defined as ≥10 foci per cell, and the percentage of positive cells per field was graphed using Prism software. The mean nuclear intensity of U373 was acquired using Xcyto10 at a 20X resolution with fluorescent intensities measured using XcytoView. The graph and statistics were generated using GraphPad 7.04 software with error bars in SEM and Log-rank (Mantel-cox) test used to generate the P-values.

Equipment and settings
----------------------

The images shown in [Figs. 1](#f1-ijo-54-06-2039){ref-type="fig"}, [S1 and S2](#SD1-ijo-54-06-2039){ref-type="supplementary-material"} were acquired using a Xcyto10 Image cytometer with a 20X objective lenses on 2 sample slides as follows: [Fig. 1](#f1-ijo-54-06-2039){ref-type="fig"} and [S1](#SD1-ijo-54-06-2039){ref-type="supplementary-material"}: MARCKS-AF546 (400 msec, LED535; 582-636), phal-loidin-AF488 (400 msec, LED488; 513-555), DAPI (400 msec, LED405; 573-613); [Fig. S2](#SD1-ijo-54-06-2039){ref-type="supplementary-material"}: MARCKS-AF546 (800 msec, LED535; 582-636), phalloidin-AF488 (800 msec, LED488; 513-555), DAPI (400 msec, LED405; 573-613). Images were acquired from XcytoView screen captures using linear scale display properties as follows: [Figs. 1](#f1-ijo-54-06-2039){ref-type="fig"} and [S1](#SD1-ijo-54-06-2039){ref-type="supplementary-material"}: TMARCKS (Min 142, Max 2207), phalloidin (Min 1874, Max 89459); DAPI (Min 1142 Max 16188)\]; [Fig. S2](#SD1-ijo-54-06-2039){ref-type="supplementary-material"}: TMARCKS (Min 44, Max 5441), phalloidin (Min 868, Max 84947); DAPI (Min 1987 Max 1524)\]. The colony formation images shown in [Fig. 3C](#f3-ijo-54-06-2039){ref-type="fig"} were acquired using a 12 MP camera (Iphone7), and the colony images shown in [Fig. 3D](#f3-ijo-54-06-2039){ref-type="fig"} were acquired under a dissecting microscope (×45 magnification) using a 12 MP camera (iPhone X). Blots were acquired on an Epson Perfection scanner.

Comet assay
-----------

A total of 100,000 cells were plated in 60-mm dishes and induced with doxycycline for 72 h. At 24 h prior to the assay, the medium was exchanged for fresh doxycycline-containing media to remove any floating cells. Cells were irradiated with 16 Gy and collected at the following time-points \[immediately post-irradiation (T0), 30 min, 1 h and 4 h\] by gently lifting them off the plate into the medium using a rubber policeman. T0 cells were irradiated on ice and scraped immediately following irradiation. The Trevigen Comet assay (Trevigen, Gaithersburg, MD, USA) was used under neutral conditions and manufacturer-provided materials and protocol. Tail moments from 200 cells per spot (3X replicates) were determined using a Zeiss AX10 observer A1 microscope and Comet Assay IV version 4.3 software. The graph was generated using tail moment values in GraphPad 7.04 software.

Immunoprecipitation coupled with mass spectrometry
--------------------------------------------------

U87 WT+ cells were cultured to 90% confluence in a 75 cm^2^ flask with standard doxycycline medium for 72 h, prior to trypsin disassociation, rinsing with PBS and flash-freezing in liquid nitrogen. The cells were later lysed in chilled MPER lysis buffer supplemented with protease (\#P8340) and phosphatase inhibitors (P0044 and P5726) (both from Sigma-Aldrich) for 30 min on ice. The lysate was centrifuged at 12,000 × g for 10 min at 4°C and protein was quantified by BCA assay. Catch and Release version 2.0 (EMD Millipore, Temecula, CA, USA) was used for immunoprecipitation with the following modifications to the manufacturer's protocol. 500 *µ*g protein was loaded into a 1.5 ml centrifuge tube, along with a 1:200 dilution of MARCKS antibody (cat. no. 20661-1-AP; Proteintech, Rosemont, IL, USA) or normal rabbit IgG antibody (sc-2027; Santa Cruz Biotechnology). The lysate antibody mixture was rotated at 4°C for 15 min. The lysate antibody mixture was then added to the spin column along with 10 *µ*l affinity ligand and 1X wash buffer for 500 *µ*l total volume. The spin column was rotated overnight at 4°C before proceeding with standard protocol eluting with 70 *µ*l of provided non-denaturing elution buffer. Flow through, washes and elutions were collected for evaluation by western blot analysis before submitting a sample to UAB mass spectrometry core for analysis. The sample was run on 10% Bistris gel and stained using the colloidal blue staining kit (LC60225; Thermo Fisher Scientific) following the manufacturer's protocol, with fixation for 10 min at room temperature using 50% methanol, 10% acetic acid and staining for 12 h at room temperature. In total, 6 separate fractions were isolated using in-gel digestion with trypsin and analyzed using an nLC LTQ Velos Pro Orbitrap mass spectrometer (Thermo Fisher Scientific) for analysis. Scaffold 4.6.2 was used to compare identified proteins from mass spectrometry experiments and generate Venn diagram. GeneGo 4.9.18 was used to generate network and pathway maps of direct protein interactions from the 108 unique proteins identified in MARCKS immunoprecipitation experiments and not detected in IgG control. Link: <https://portal.genego.com/>

Orthotopic implantation, cranial radiation and survival analysis
----------------------------------------------------------------

All animal studies were carried out in accordance with the policies set by the University of Alabama (UAB) Institutional Animal Care and Use Committee (IACUC) and performed according to their guidelines. Moreover, the experimental protocols were registered and approved by the UAB Occupational Health and Safety (Project no. 14-124). Five- to six-week-old female athymic nude mice (Charles River, Hartford, CT, USA) were started on doxycycline chow 1 week prior to an intracranial injection of 500,000 cells per mouse with the aid of UAB's Brain Tumor Animal Model Core. A total of 40 mice (20 for data shown in [Fig. 1A](#f1-ijo-54-06-2039){ref-type="fig"} and 20 for data shown in [Fig. S3](#SD1-ijo-54-06-2039){ref-type="supplementary-material"}) were used with an average weight of 20-22 g per mouse. All mice were housed under the care and maintenance of UAB's fully accredited (AAALAC) animal resources program (ARP) with routine monitoring by veterinarians. Mice were housed no more than 6 to a cage and had 24-h access to food and water maintained daily. The animal room was maintained at 21°C and 50% humidity with 12-h light-dark cycles. Intracranial injections were carried out as previously described ([@b36-ijo-54-06-2039]). In brief cells were suspended in a (1:1) mixture of methylcellulose and loaded into a 1 ml Hamilton syringe with a 12-gauge needle. Mice were anesthetized using an intraperitoneal injection of ketamine (100 mg/kg) and xylazine (15 mg/kg), and a midline scalp incision was made and a burr hole was drilled 1 mm posterior to the coronal suture and 2 mm right of the midline. Subsequently, 5 *µ*l of cell mixture was stereotactically delivered to a depth of 2.5 mm into the right caudate-putamen of each mouse. The data shown in [Fig. 1A](#f1-ijo-54-06-2039){ref-type="fig"} are composed of 4 groups with 5 mice in each (2 with CTL, 2 with WT+) with 1 group of each cell type receiving either 12 Gy (6 by 2 Gy fractions) or sham irradiation (0 Gy). Mice were euthanized at the first appearance of neurological symptoms or at the request of veterinary staff using CO~2~ exposure at 20% chamber volume displacement/minute (1.5 l/min in an IACUC approved chamber with a flow meter) for \~5 min followed by secondary cervical dislocation as per the AVMA guidelines. Brains were collected and halved through the injection site for preservation by both formalin and liquid nitrogen.

Statistical analysis and data reproducibility
---------------------------------------------

All statistical analyses were calculated in Prism 8.0 (GraphPad) with P-values \<0.05 considered to indicate statistically significant differences. Significance in [Fig. 1](#f1-ijo-54-06-2039){ref-type="fig"} was calculated with the Log-rank (Mantel-Cox) test, and in [Fig. 2](#f2-ijo-54-06-2039){ref-type="fig"}, with the similarity score log-transformed Pearson's correlation. In [Fig. 3](#f3-ijo-54-06-2039){ref-type="fig"}, significance (A and B) was determined using one-way ANOVA with Dunnett's multiple comparison test, or (C) a two tailed t-test. In [Fig. 4](#f4-ijo-54-06-2039){ref-type="fig"}, significance was determined using two-way ANOVA with Dunnett's multiple comparison test. All experiments were repeated at least 2 times.

Results
=======

MARCKS overexpression prolongs survival and enhances radiation sensitivity in GBM in vivo
-----------------------------------------------------------------------------------------

We have previously shown that MARCKS protein expression is inversely associated with GBM proliferation and intracranial xenograft growth rates, with the knockdown of MARCKS in the PTEN-null line, U251, resulting in an enhanced radiation resistance ([@b33-ijo-54-06-2039]). In this study, to establish whether MARCKS overexpression can inhibit GBM growth and enhance radiation sensitivity, we orthotopically implanted the PTEN-null U87 cell line featuring a tetracycline-inducible, V5-tagged MARCKS vector (WT+) ([@b25-ijo-54-06-2039]) or an empty control vector (CTL) into athymic nude mice and assessed the effects on survival. The WT+ mice were found to have a median survival of 31 days without radiotherapy (RT) and a 56-day survival following RT at 12 Gy (25-day enhancement), whereas the CTL mice had a median survival of 22 days without RT and a 42-day median survival with RT (20-day enhancement) ([Fig. 1A](#f1-ijo-54-06-2039){ref-type="fig"}). MARCKS overexpression increased the survival of the mice compared with the CTL group by 40% (9 days), while the WT+ mice receiving RT had an additional 25% (5 days) increase in survival compared with the CTL mice ([Fig. 1A](#f1-ijo-54-06-2039){ref-type="fig"}). The successful overexpression of MARCKS *in vivo* was verified in post-mortem tumors by immunohistochemical staining ([Fig. 1B](#f1-ijo-54-06-2039){ref-type="fig"}). These data support the hypothesis that the overexpression of MARCKS is capable of suppressing growth and enhancing radiation sensitivity in PTEN-null GBM.

MARCKS ED mutants mimic actin binding and the cellular localization of MARCKS phosphorylation in GBM
----------------------------------------------------------------------------------------------------

We then investigated the mechanisms through which the phosphorylation of the 4 serine residues present in MARCKS ED affect the ability of MARCKS to suppress GBM growth and radiation resistance by generating additional ED mutants: i) A non-phosphorylatable ED mutant (NP) replaced the serine residues with alanine, to prevent the loss of plasma membrane binding by phosphorylation; ii) a pseudo-phosphorylated ED mutant (PP) substituted the serine residues with aspartic acid, which prevented membrane binding by mimicking negatively charged phosphorylation groups; and iii) a deleted effector domain mutant (ΔED) that lacks an ED ([Fig. 2A](#f2-ijo-54-06-2039){ref-type="fig"}). To evaluate the cellular localization of the MARCKS mutants, immunofluorescent imaging, and the analysis of the mutants 72 h following doxycycline induction were performed using the image cytometer Xcyto10. An unphosphorylated non-Ca^2+^/CaM bound ED is required for MARCKS membrane binding and F-actin crosslinking ([@b13-ijo-54-06-2039],[@b37-ijo-54-06-2039]) allowing ΔED to serve as a cytoplasmic control. MARCKS that co-localizes well with F-actin is consistent with an unphosphorylated ED, whereas MARCKS that co-localizes poorly with F-actin may indicate ED phosphorylation or binding to Ca^2+^/CaM ([@b14-ijo-54-06-2039]). Imaging revealed WT+ and NP MARCKS to have substantial co-staining with phalloidin (F-actin stain), while the PP and ΔED MARCKS lacked co-staining with F-actin and appeared predominantly cytoplasmic with perinuclear enrichment. Slight decreases in F-actin intensity were observed in all MARCKS mutants compared with the control ([Fig. 2B](#f2-ijo-54-06-2039){ref-type="fig"}). [Fig. 2C](#f2-ijo-54-06-2039){ref-type="fig"} highlights the differences in MARCKS staining between PP and ΔED with minimal F-actin co-staining and prominent perinuclear staining, while NP shows substantial co-staining with F-actin ([Fig. 2C](#f2-ijo-54-06-2039){ref-type="fig"}). The quantification of MARCKS and F-actin co-staining revealed that both WT+ and NP MARCKS co-stained strongly with F-actin, while the CTL, PP and ΔED lines did not ([Fig. 2D](#f2-ijo-54-06-2039){ref-type="fig"}). The imaging of uninduced MARCKS U87 mutants can be observed for comparison in [Fig. S1](#SD1-ijo-54-06-2039){ref-type="supplementary-material"}. The overexpression of WT+ MARCKS in an additional PTEN-null line (U373) revealed that MARCKS was predominantly membrane-associated and perinuclear with a slight increase in actin co-localization ([Fig. S2](#SD1-ijo-54-06-2039){ref-type="supplementary-material"}). These data indicate that the localization of WT+ and NP MARCKS mutants is consistent with an ED that is unphosphorylated and membrane-bound, while the PP mutant mimics the cytoplasmic localization of phosphorylated MARCKS.

MARCKS ED phosphorylation overcomes MARCKS growth suppression and promotes colony formation in vitro
----------------------------------------------------------------------------------------------------

To identify differences in GBM growth with MARCKS overexpression and the potential effects of ED phosphorylation, we measured the growth of our MARCKS mutants 7 days following doxycycline induction. Statistically significant (P\<0.0001) decreases in growth were observed in the WT+ and NP mutants, and no decrease in growth in PP or ΔED compared to the CTL line ([Fig. 3A](#f3-ijo-54-06-2039){ref-type="fig"}). The comparison of mutants under PBS and doxycycline conditions is available in [Fig. S1](#SD1-ijo-54-06-2039){ref-type="supplementary-material"} using ATPlite proliferation assay. Colony formation assays revealed NP MARCKS to trend towards (P=0.076) a decrease in colony number compared to CTL, while PP exhibited significant (P=0.001) increases in the number of colonies. WT+ (P=0.61) and ΔED (P=0.85) exhibited no significant differences in colony number ([Fig. 3B](#f3-ijo-54-06-2039){ref-type="fig"}). Colonies formed by PP were also larger and contained more cells per colony on average compared with CTL and other mutants ([Fig. 3C](#f3-ijo-54-06-2039){ref-type="fig"}). A magnified view of NP and PP colony differences (solid arrow) can be seen in [Fig. 3D](#f3-ijo-54-06-2039){ref-type="fig"}. The orthotopic implantation of these ED mutants into mice, however, did not reveal significant differences in survival between the ED mutants, suggesting that MARCKS ED phosphorylation may not fully account for the MARCKS survival benefit ([Fig. S3](#SD1-ijo-54-06-2039){ref-type="supplementary-material"}). The growth-suppressive effects of MARCKS overexpression (WT+) were additionally observed in the PTEN-null U373 GBM cell line (P=0.0010) ([Fig. 3E](#f3-ijo-54-06-2039){ref-type="fig"}), although we lacked NP and PP ED mutants in U373 for additional validation.

Both AKT activation ([@b6-ijo-54-06-2039]) and PKCα protein expression ([@b38-ijo-54-06-2039]) are associated with enhanced cancer growth, proliferation and survival signaling, and the knockdown of MARCKS in GBM has been previously shown to enhance AKT phosphorylation ([@b33-ijo-54-06-2039]) and decrease PKCα levels ([@b32-ijo-54-06-2039]). In this study, we examined the mechanisms through which the overexpression of MARCKS ED mutants affect these features and found that WT+ and NP MARCKS overexpression decreased the activation of AKT (T308 and S473 phosphorylation) by 45 and 32%, respectively compared to the PBS-treated cells, while CTL and PP exhibited negligible suppression. No effects were observed on PKCα expression with the overexpression of our MARCKS mutants ([Fig. 3F](#f3-ijo-54-06-2039){ref-type="fig"}). Overall, we found that MARCKS overexpression (WT+) suppressed GBM growth and the data suggest that it is the unphosphorylated ED (NP), which suppresses growth and AKT activation, while the phosphorylated ED (PP) does not. Since differences in AKT activation suggest differences in radiation sensitivity ([@b39-ijo-54-06-2039]), we then investigated the effects of MARCKS ED phosphorylation on radiation sensitivity.

MARCKS ED phosphorylation modifies GBM sensitivity to radiation
---------------------------------------------------------------

Previous experiments in our laboratory have demonstrated that the inhibition of MARCKS ED phosphorylation or the overexpression of NP MARCKS in a lung cancer line sensitized them to radiation ([@b35-ijo-54-06-2039],[@b40-ijo-54-06-2039]). The GBM data in this study demonstrated that the overexpression of WT+ MARCKS enhanced radiation sensitization *in vivo*. To determine the mechanisms through which the MARCKS ED phosphorylation state affects radiation sensitivity, we first assessed our mutants using a clonogenic assay. We found NP MARCKS mutants to have the lowest clonogenic survival following escalating doses of radiation, showing radiation sensitization compared with CTL. WT+ exhibited a mild enhancement in radiation sensitivity compared with the control, while PP exhibited slightly decreased sensitivity (dose enhancement ratios at surviving fraction 0.2: CTL =1, WT+ =1.2, N =1.5 and PP =0.87) ([Fig. 4A](#f4-ijo-54-06-2039){ref-type="fig"}). To investigate potential alterations in DNA repair, we then examined the phosphorylation of histone H2AX at S139 (γH2AX) as a surrogate for DNA damage. At 1 h post-8 Gy single fraction radiotherapy, the WT+ (P=0.0021) and NP (P=0.0111) mutants exhibited prolonged increases in γH2AX levels compared with the control, whereas PP (P=0.0116) exhibited a slight decrease. At 4 h, no statistically significant increases in γH2AX were observed compared with CTL; however, NP did trend towards a significant increase (P=0.2609) ([Fig. 4B](#f4-ijo-54-06-2039){ref-type="fig"}). Due to the considerable radiation resistance of U87 cells and variations in the cell cycle that alter individual cell radiation sensitivity ([@b41-ijo-54-06-2039]) we used an elevated 16 Gy dose of radiotherapy to directly quantify the formation and resolution of double-strand DNA (dsDNA) breaks using a neutral comet assay ([Fig. 4C](#f4-ijo-54-06-2039){ref-type="fig"}). NP exhibited the greatest and most significant increases in the tail moment compared to CTL both at 1 h (P\<0.0001) and 4 h (P=0.0012) post-irradiation compared with CTL. WT+ had a lower basal amount of DNA damage immediately following 16 Gy (T0) and at 30 min; however at 1 h, WT+ displayed sustained DNA damage (P=0.0067) compared with the control. PP also had a lower induction of double-strand DNA damage immediately following RT and a similar return to baseline as the control ([Fig. 4C](#f4-ijo-54-06-2039){ref-type="fig"}). The overexpression of WT+ MARCKS in U373 GBM cells similarly revealed increased yH2AX nuclear staining ([Fig. S1C](#SD1-ijo-54-06-2039){ref-type="supplementary-material"}) and RT sensitivity measured by clonogenic assay ([Fig. 4D](#f4-ijo-54-06-2039){ref-type="fig"}), although we lacked ED mutants for additional validation. These data support prior findings that MARCKS is involved in that DNA damage response ([@b33-ijo-54-06-2039],[@b40-ijo-54-06-2039]) and suggest that an unphosphorylated ED promotes MARCKS radiation sensitization *in vitro*.

Identification of MARCKS protein-protein interactions in GBM using immunoprecipitation coupled to mass spectrometry
-------------------------------------------------------------------------------------------------------------------

MARCKS is known to be phosphorylated by PKC and ROCK and dephosphorylated by protein phosphatase 2 (PP2A), which alter its ability to bind Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~, actin, and Ca^2+^/CaM ([@b10-ijo-54-06-2039]). Recently, MARCKS ED has been shown to function as an NLS allowing it to translocate into the nucleus of GBM and bind nuclear Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~ ([@b25-ijo-54-06-2039]). In this study, to identify novel protein-protein interactions of MARCKS in GBM, we immunoprecipitated MARCKS in the WT+ overexpressing U87 cell line and detected protein interactions with high-resolution mass spectrometry. The successful pulldown of MARCKS was verified by western blot analysis before proceeding with in-gel digestion, liquid chromatography and high-resolution mass spectrometry ([Fig. 5A](#f5-ijo-54-06-2039){ref-type="fig"}). A total of 275 proteins were detected in the two separate MARCKS IP that was not found in the IgG control, 108 of which were identified in both fractions ([Fig. 5B](#f5-ijo-54-06-2039){ref-type="fig"}). A GeneGo pathway analysis map was constructed from these 108 proteins showing only direct protein interactions ([Fig. 5C](#f5-ijo-54-06-2039){ref-type="fig"}). A common pathway map was similarly generated in GeneGo to determine the potential signaling interactions of MARCKS ([Fig. 5D](#f5-ijo-54-06-2039){ref-type="fig"}). The top protein pathway interactions found were involved in cytoskeletal remodeling and the regulation of the actin cytoskeleton and non-homologous end joining (NHEJ) DNA repair pathway. Notable direct protein interactions of interest with MARCKS found using this technique include importin β-2 (transportin-1), a nuclear import chaperone that binds nuclear localization sequences, and Ku70, a protein involved in DNA repair. However, additional validation of these targets at endogenously expressed MARCKS levels is still required.

Discussion
==========

GBM remains a devastating disease driven by high rates of growth, therapeutic resistance and invasiveness, which ultimately results in recurrence. Developing a better understanding of the molecular mechanisms that contribute to this aggressiveness is essential to developing future effective therapeutic strategies. Over 80% of GBM cases contain activating mutations in RTKs/PI3K/AKT or the loss of PTEN ([@b6-ijo-54-06-2039]). These mutations all contribute to dysregulations in Ptdlns ([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~ signaling, which promotes cell proliferation, differentiation ([@b42-ijo-54-06-2039],[@b43-ijo-54-06-2039]), invasion ([@b32-ijo-54-06-2039]) and therapeutic resistance ([@b44-ijo-54-06-2039]-[@b46-ijo-54-06-2039]) pathways, rendering this signaling axis an ideal therapeutic target ([@b6-ijo-54-06-2039],[@b47-ijo-54-06-2039]). To date, however, small molecule inhibitors targeting this pathway have had minimal success in GBM ([@b48-ijo-54-06-2039],[@b49-ijo-54-06-2039]). One potential reason for this failure lies in an incomplete understanding of regulators of this pathway, such as MARCKS ([@b10-ijo-54-06-2039]). MARCKS is a well-known regulator of Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~ levels ([@b50-ijo-54-06-2039]-[@b52-ijo-54-06-2039]), which plays a vital role in AKT activation that drives cell proliferation, chemo- and radiation resistance ([@b45-ijo-54-06-2039],[@b46-ijo-54-06-2039],[@b53-ijo-54-06-2039]). MARCKS expression has had a confusing association with both positive and negative prognosis across different cancer types ([@b10-ijo-54-06-2039],[@b26-ijo-54-06-2039]-[@b28-ijo-54-06-2039],[@b54-ijo-54-06-2039],[@b55-ijo-54-06-2039]), and this ambiguity over the role of MARCKS in cancer has been attributed to potential differences MARCKS ED phosphorylation ([@b10-ijo-54-06-2039],[@b30-ijo-54-06-2039],[@b56-ijo-54-06-2039]). The phosphorylation of MARCKS ED by PKC or ROCK kinases results in the translocation of MARCKS off the plasma membrane, prevents its binding to PS ([@b24-ijo-54-06-2039]), Ca^2+^/calmodulin and crosslinking of actin filaments, and releases sequestered Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~ ([@b18-ijo-54-06-2039],[@b57-ijo-54-06-2039],[@b58-ijo-54-06-2039]). MARCKS ED also serves as an NLS ([@b25-ijo-54-06-2039]), and differences in its phosphorylation are also likely to regulate nuclear import. Indeed, we detected differences in the nuclear localization of our PP ED mutant from WT+ and NP ED mutant that needs additional future validation in a model system with endogenous MARCKS expression ([Fig. S4](#SD1-ijo-54-06-2039){ref-type="supplementary-material"}). Due to the important role of Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~ in oncogenic signaling ([@b8-ijo-54-06-2039]), the frequent mutations of GBM altering Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~ signaling ([@b6-ijo-54-06-2039]), and the role of MARCKS in regulating Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~ availability ([@b59-ijo-54-06-2039]), in this study, we evaluated the effects of MARCKS expression and ED phosphorylation on GBM growth and therapeutic resistance.

The current study supports previous *in vitro* findings that the loss of MARCKS enhances growth and radiation resistance in a PTEN-null GBM line ([@b33-ijo-54-06-2039]). Through the overexpression of WT+ MARCKS in an intracranial tumor model, we further established MARCKS expression enhanced survival and radiation responses compared to empty vector control (CTL) mice. To determine the mechanisms through which the phosphorylation of MARCKS ED may alter these tumor-suppressing effects, we mimicked ED phosphorylation or prevented phosphorylation through substitution of the 4 ED serine residues. MARCKS functions as an electrostatic switch based on it ED phosphorylation status ([@b13-ijo-54-06-2039]), with F-actin and plasma membrane binding with an unphosphorylated ED, and the loss of F-actin membrane binding after phosphorylation. Additionally, ΔED functions as a cytoplasmic control as the ED contains both the actin-binding domain and the poly-lysine (+13) electrostatic attraction to the plasma membrane ([@b13-ijo-54-06-2039]). The ED mutants were found to appropriately mimic MARCKS ED phosphorylation state with NP co-localizing with F-actin at the plasma membrane, while PP and ΔED mutants localized to the cytoplasmic and perinuclear region. WT+ closely mimicked NP with high levels of F-actin co-localization and similar morphologic appearance suggesting the majority of overexpressed MARCKS was membrane-bound. Although slight decreases in filamentous actin staining were observed following the overexpression of MARCKS in all our mutant lines compared with control or uninduced group, no substantial differences existed between the ED mutants. This suggested cytoskeletal impairment was not a major factor in the phenotypic differences of our mutants.

We then examined the effects of MARCKS ED phosphorylation on GBM growth by measuring its effects on cell viability using ATP luminescence ([@b60-ijo-54-06-2039]). To control for potential metabolic disturbances occurring from lentiviral transduction or doxycycline exposure we used the empty vector CTL line for comparison of the effects of MARCKS ED mutant expression. We found the WT+ and NP MARCKS overexpression led to significant decreases in cell viability (P\<0.0001), while the PP or ΔED mutants did not suppress viability. The significant suppression of cell viability in WT+ and NP (P=0.004 and P=0.0093, respectively) was dependent on exposure of the mutants to doxyxcline, and its resulting expression of mutant MARCKS protein, with no significant decreases in viability seen in CTL or PP as observed in [Fig. S1B](#SD1-ijo-54-06-2039){ref-type="supplementary-material"}. The cytotoxic effects of MARCKS expression were not observed; thus, this decreased cell viability was attributed to decreased proliferation. Although ATP levels are a reliable measure of metabolic viability and typically, cell number, ATP can also be altered by circadian rhythms, proliferation and differentiation, which we did not differentiate from ([@b61-ijo-54-06-2039]). We utilized the colony formation assay as a second assay for investigating MARCKS growth effects.

Colony formation assay, which estimates the proportion of cells capable of 'unlimited' replication, revealed that NP trended towards a decrease in colony forming ability, while PP significantly enhanced colony formation. This increased number and size of the colonies would indicate that PP MARCKS may enhance the proliferative capacity of GBM. Differential growth effects of MARCKS have previously described in epithelial and vascular smooth muscle cells, although differences in ED phosphorylation status were not investigated ([@b62-ijo-54-06-2039]). However, testing *in vivo* failed to reveal statistically significant differences in the median survival (one-way ANOVA P=0.0879) or mitotic counts (one-way ANOVA P=0.1587) between MARCKS mutants and control. This suggests ED phosphorylation may have a less definitive roll in affecting overall survival. The weak correlation of mitotic counts to survival time is confounded by the fact mitotic counts were acquired at the time of sacrificing opposed to a similar time-point. Potential reasons for these *in vivo*, *in vitro* differences, include MARCKS ED phosphorylation may function more in releasing MARCKS inhibition on the proliferative capacity than directly driving proliferation, especially under the different microenvironmental conditions, such as limited nutrient and oxygen availability of the intracranial growth environment. Additionally, MARCKS may enhance survival in GBM ways not directly altered by ED phosphorylation. The investigation of MARCKS ED phosphorylation on p-AKT (T308/S473) revealed WT+ and NP MARCKS overexpression suppressed p-AKT levels, while PP MARCKS did not in GBM. These data support other findings that ED phosphorylation is an important regulator of this pathway ([@b10-ijo-54-06-2039]). No effect was observed on PKCα expression with or MARCKS overexpression model as previously reported in a GBM EGFR-VIII line, suggesting that EGFR-VIII expression may be essential for MARCKS-driven PKCα expression differences ([@b32-ijo-54-06-2039]).

MARCKS knockdown was previously shown to enhance the NHEJ DNA repair mechanism and radiation resistance in GBM ([@b33-ijo-54-06-2039]). Consistent with this, in this study, we found that MARCKS overexpression (WT+) in U87 and U373 cells increased radiation sensitivity. Investigating the effects of ED phosphorylation on MARCKS radiation sensitization, we found that the NP mutant was radiation-sensitive by clonogenic assay, γH2AX, and comet assay, while the PP mutant was not. The clonogenic assay measures the cumulative effects of radiation on survival, including cell death, senescence, metabolic disturbances, that may take generations to develop and is considered the most sensitive *in vitro* radiation sensitivity assay ([@b63-ijo-54-06-2039]). NP was found to have a prolonged presence of γH2AX quantified as a percentage of cells with \>10 foci per cell. However, the PP mutant revealed prolonged γH2AX staining in some instances when quantified by mean nuclear intensity ([Fig. S1](#SD1-ijo-54-06-2039){ref-type="supplementary-material"}), although this result was inconsistent with the comet assay, clonogenic assay findings, and traditional foci count methodology. The high level of radiation resistance by U87 cells ([@b41-ijo-54-06-2039]) and the differences in sensitivity between γH2AX quantification methods may account for these differences, which can be minimized with higher doses or radiation ([@b64-ijo-54-06-2039]). Higher 16 Gy doses of radiotherapy were needed for significant neutral comet assay results. NP also exhibited the most prolonged increase in dsDNA breaks following RT, most closely reflecting the clonogenic assay findings in suggesting it is radiation sensitive. Immediately following irradiation (T0), WT and PP showed lower levels of dsDNA, however, at 1 h WT+ also exhibited a significant (P=0.0067) elevation of DNA damage relative to the control, while PP did not. As such, we propose that the membrane-bound, unphosphorylated form of MARCKS promotes radiation sensitization.

Utilizing IP/MS of MARCKS in U87 cells, we identified known MARCKS interactors including PP2A, known to dephosphorylate MARCKS ED, and N-myristoyltransferase (NMT) which preferentially myristoylated MARCKS over many other myristoylated proteins ([@b65-ijo-54-06-2039]). These exploratory studies suggest a number of new interacting partners that can be validated in future studies. Rho GTPases including LIMK1 and Rho GDP-dissociation inhibitor 1 were also detected and are important regulators of the actin cytoskeleton promoting cell migration ([@b66-ijo-54-06-2039]). We detected a notable interaction with transportin-1a nuclear import protein that regulates nuclear-cytoplasmic transport through adapter proteins ([@b67-ijo-54-06-2039]). Transportin-1 and MARCKS interactions are previously unreported, but are consistent with emerging data that MARCKS is selectively imported into the nucleus in specific cell types ([@b68-ijo-54-06-2039]), and our findings that only the PP mutant was not enriched in the nucleus suggests ED phosphorylation may inhibit its translocation through the nuclear membrane. Interaction with casein kinase 2 (CK2) and its central location in MARCKS protein network suggest it may also directly regulate MARCKS at the ED or other phosphorylation domains. CK2 has previously been shown to phosphorylate proteins regulating their nuclear localization ([@b69-ijo-54-06-2039]), regulate the cell cycle, NHEJ DNA repair and WNT signaling ([@b70-ijo-54-06-2039]), and mediate non-canonical WNT signaling through PKCΔ ([@b71-ijo-54-06-2039]). Several interactions with nuclear proteins were detected that were involved in DNA repair including XRCC6 (Ku70), TEP1 and SSRP1, suggesting that MARCKS may play a direct role in DNA repair mechanism beyond Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~ sequestration. Perinuclear proteins involved in endoplasmic reticulum calcium homeostasis including CHERP and TRAPG were identified, along with Myoferlin, a calcium/phospholipid binding-protein with a role in plasmalemma repair. Lastly, MARCKS has previously been shown to become phosphorylated by elevated levels of H~2~O~2~ in a PKCΔ dependent manner ([@b72-ijo-54-06-2039]). The potential interaction with peroxiredoxin 1a, a regulator of intracellular H~2~O~2~ signaling previously shown to be involved in promoting invasion, radiation and chemotherapy resistance ([@b73-ijo-54-06-2039]), further strengthens the relationship of H~2~O~2~ signaling and MARCKS. Future studies investigating H~2~O~2~ effects on GBM growth and invasion should be considered due to H~2~O~2~ use during GBM resection for tumoricidal effects ([@b74-ijo-54-06-2039]). H~2~O~2~ use at subtherapeutic levels may in theory trigger invasive and proliferative effects seen with MARCKS phosphorylation ([@b32-ijo-54-06-2039]).

The limitations of this study include the use of a doxycycline-inducible model with overexpression of MARCKS ED mutants, as opposed to testing at endogenous MARCKS levels with true serine phosphorylation, and the lack of additional NP and PP ED mutants that could be tested in PTEN null cell lines. Due to the dynamic and differential effects MARCKS ED can have in regulating cellular functions ([@b62-ijo-54-06-2039]), the impact of MARCKS expression and ED phosphorylation should be carefully considered in other model systems and signaling environments, such as serum-free growth conditions to establish the effects of MARCKS.

In conclusion, the intrinsically unstructured nature and electrostatic properties of MARCKS allow it to have a broad range of cellular interactions regulated by its centrally located 25 amino acid ED. At a minimum, MARCKS ED binds or responds to: Ptdlns([@b4-ijo-54-06-2039],[@b5-ijo-54-06-2039])P~2~ ([@b19-ijo-54-06-2039]), phosphatidylserine ([@b24-ijo-54-06-2039]), F-actin crosslinking ([@b58-ijo-54-06-2039]), phosphorylation by PKC and ROCK kinases and binding to Ca^2+^/calmodulin ([@b10-ijo-54-06-2039]), intracellular calcium levels ([@b13-ijo-54-06-2039]), and H~2~O~2~ signaling ([@b72-ijo-54-06-2039]) allowing it to coordinate cellular functions, such as vesicle release ([@b75-ijo-54-06-2039]), cell migration ([@b76-ijo-54-06-2039]), proliferation and differentiation ([@b42-ijo-54-06-2039],[@b43-ijo-54-06-2039],[@b62-ijo-54-06-2039]). MARCKS plays a potential role in cancer stemness that needs future evaluation ([@b77-ijo-54-06-2039]). Prior to this study, MARCKS knockdown was associated with enhanced GBM growth and radiation resistance ([@b33-ijo-54-06-2039]), and the phosphorylation of MARCKS ED was associated with enhanced invasion ([@b32-ijo-54-06-2039]) with an undetermined effect on growth and radiation sensitivity in GBM. This study investigated the mechanisms through which ED phosphorylation regulates MARCKS cellular localization, and in turn, examined the effects of MARCKS on growth suppression and radiation sensitivity in PTEN-null GBM. We find that NP MARCKS to exhibited a similar suppression of growth and AKT activation and enhancement radiation sensitivity as WT+ overexpression, while the PP mutant did not exhibit these features. This study suggests that MARCKS ED phosphorylation may be a method with which to overcome MARCKS growth-suppressing and radiation-sensitizing effects and that the determination of the ED phosphorylation status is vital to understanding the potential effects of MARCKS expression.
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![MARCKS overexpression prolongs survival and enhances radiation sensitivity *in vivo*. (A) U87 cells were orthotopically injected into the caudate putamen of five- to six-week-old athymic nude mice on doxycycline chow. Survival was determined at the first sign of neurologic symptoms. Mice that received RT mice received 12 Gy RT delivered in 2 Gy fractions 3 times a week (n=5). (B) Coronal slices of brains were collected at the day of sacrifice to verifying MARCKS induction by doxycycline diet via the presence of exogenous MARCKS V5 tag. P-values calculated using the Log-rank (Mantel-Cox) test. MARCKS, myristoylated alanine-rich C-kinase substrate; RT, radiotherapy. WT+, V5-tagged MARCKS vector; CTL, control.](IJO-54-06-2039-g00){#f1-ijo-54-06-2039}

![MARCKS ED phosphorylation regulates actin binding and the cellular localization of MARCKS in GBM. (A) Diagram of MARCKS effector domain mutants. WT+ has 4 PKC phosphorylatable serine residues in the effector domain. NP mutant replaces the 4 serine residues with alanine, PP replaces serines with aspartic acid residue and ΔED has a deleted effector domain. (B) Immunofluorescent imaging of U87 MARCKS effector domain mutants 72 h after doxycycline induction using the image cytometer Xcyto10 (×20 magnification). (C) Magnified view of MARCKS staining in NP, and PP mutants. Note the ruffled appearance of NP in contrast to the perinuclear staining of PP (×20 magnification, 400% zoom). (D) Quantification of co-localization using similarity score to phalloidin (F-actin) calculated in XcytoView. The similarity score is calculated from the log-transformed Pearson's correlation between two separate fluorescent channels within the indicated compartment, graphed as mean ± SEM. MARCKS, myristoylated alanine-rich C-kinase substrate; ED, effector domain; WT+, V5-tagged MARCKS vector; CTL, control; NP, non-phosphorylatable ED mutant; PP, pseudo-phosphorylated ED mutant; ΔED, deleted effector domain mutant.](IJO-54-06-2039-g01){#f2-ijo-54-06-2039}

![MARCKS ED phosphorylation overcomes the growth suppressive effects of MARCKS. (A) A total of 5,000 cells were plated in a black-walled 96 well plate with doxycycline and assessed for cell viability at day 7 using ATPlite assay (n=12). Comparison of mutants PBS vs. doxycycline induction is shown in Fig. S1. (B) Quantification of colonies at day 14 day containing \>50 cells after plating 2,000 cells per plate. (C) Image of colony formation at day 14. (D) Magnified view of NP and PP colonies from colony formation 14 days after plating (×10 magnification). The solid arrows indicate example colonies. (E) A total of 5,000 cells were plated in a black-walled 96 well plate with doxycycline and assessed using CellTiter glow cell viability assay at 5 days in U373 (n=4). (F) Western blot analysis demonstrating the inducible nature of MARCKS expression 7 days after treating with 2 *µ*g/ml doxycycline, and the effects on activated AKT (T308 and S473), AKT and PKCα expression. All probing done on same membrane with stripping. Cropped boundaries indicated by black line. Full-length blots and probing order are available in Fig. S5. Adjusted relative densitometry of p-AKT between Dox-induced and PBS un-induced (=1) calculated in ImageJ (CTL=0.962, WT+=0.549, NP=0.678, PP=1.05). Statistical analysis was carried out in GraphPad Prism using (A and B) ordinary one-way ANOVA with Dunnett's multiple comparison tests to CTL, or (E) two-tailed t-test. Data are the means ± SEM. ^\*\*^P\<0.01, ^\*\*\*^P\<0.001 and ^\*\*\*\*^P\<0.0001, compared to CTL. MARCKS, myristoylated alanine-rich C-kinase substrate; ED, effector domain; WT+, V5-tagged MARCKS vector; CTL, control; NP, non-phosphorylatable ED mutant; PP, pseudo-phosphorylated ED mutant; ΔED, deleted effector domain mutant.](IJO-54-06-2039-g02){#f3-ijo-54-06-2039}

![Unphosphorylated MARCKS ED is associated with greater radiation sensitivity in GBM. (A) Clonogenic survival assay of U87 MARCKS ED mutants receiving escalating doses of ionizing radiation plotted in a semilogarithmic manner with SEM error bars (n=4). (B) Mean nuclear yH2AX intensity following 8 Gy RT measured in a blinded manner by counting the percentage of cells with greater than 10 foci per 20X field. (4 fields per measurement). (C) Quantification of double-strand DNA breaks following 16 Gy RT by measurement of comet tail moment (n\>200). (D) Clonogenic survival assay of U373 dox 14 days after escalating doses of radiation (n=3). (B and C) Statistical analysis was carried out in GraphPad Prism using two-way ANOVA with Dunnett's multiple comparison tests to CTL. Data are the means ± SEM. ^\*\*^P\<0.01, ^\*\*\*^P\<0.001 and ^\*\*\*\*^P\<0.0001, compared to CTL. MARCKS, myristoylated alanine-rich C-kinase substrate; ED, effector domain; WT+, V5-tagged MARCKS vector; CTL, control; NP, non-phosphorylatable ED mutant; PP, pseudo-phosphorylated ED mutant.](IJO-54-06-2039-g03){#f4-ijo-54-06-2039}

![MARCKS protein-protein interactions identified by immunoprecipitation coupled with in-gel digestion, liquid chromatography, and high-resolution mass spectrometry. U87 WT+ was doxycycline-induced for 72 h before lysis using MPER. (A) immunoprecipitation was performed in WT+ lysate with catch and release V2.0 system and MARCKS rabbit pAB or IgG rabbit control antibody. Successful IP was confirmed by western blot analysis using MARCKS mouse monoclonal antibody. (B) Venn diagram of 108 unique proteins detected in 2 separate MARCKS IP's not found in IgG control. Scaffold_4.6.2 was used to generate the graph. Protein threshold (80%), Min \# peptides ([@b1-ijo-54-06-2039]), Peptide threshold (80%). (C) network map or (D) pathway map generated from the 108 unique proteins using GeneGo 4.9.18 plotting direct interactions and exclusion of orphan nodes. MARCKS, myristoylated alanine-rich C-kinase substrate; WT+, V5-tagged MARCKS vector.](IJO-54-06-2039-g04){#f5-ijo-54-06-2039}
